Bamlanivimab was authorized for use in relation to the COVID-19 pandemic, in accordance with the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 . The CPM for bamlanivimab was updated on 14 April 2021 with information concerning SARS-CoV-2 variants of concern.
RecallTracker